We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+42.66%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.34B
Cap. Flow
+$190M
Cap. Flow %
3.85%
Top 10 Hldgs %
100%
Holding
8
New
3
Increased
2
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BLTE
Belite Bio
BLTE
+$359M
2
INSM icon
Insmed
INSM
+$86.8M
3
WVE icon
Wave Life Sciences
WVE
+$74.2M
4
CAPR icon
Capricor Therapeutics
CAPR
+$10.4M
5
ABVX
Abivax
ABVX
+$1.53M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$318M
2
QURE icon
uniQure
QURE
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$3.64B 73.78%
20,933,277
+475,832
+2% +$86.8M
BLTE
2
Belite Bio
BLTE
$6.02B
$487M 9.86%
+3,027,704
New +$359M
ABVX
3
Abivax
ABVX
$11.9B
$440M 8.9%
3,178,501
+14,000
+0.4% +$1.53M
CDTX
4
DELISTED
Cidara Therapeutics
CDTX
$220M 4.46%
997,196
– –
WVE icon
5
Wave Life Sciences
WVE
$1.12B
$125M 2.53%
+7,298,421
New +$74.2M
CAPR icon
6
Capricor Therapeutics
CAPR
$1.13B
$23.2M 0.47%
+800,000
New +$10.4M
QURE icon
7
uniQure
QURE
$2.77B
– –
-400,000
Closed -$23.8M
UTHR icon
8
United Therapeutics
UTHR
$22.7B
– –
-748,550
Closed -$318M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q4 2025 Portfolio in Review

As of Q4 2025, Darwin Global Management held 8 positions worth $4.94B, up 37% from $3.6B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $190M of net new capital in Q4 2025, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Belite Bio: 3,027,704 shares worth $487M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was United Therapeutics, an estimated $318M sold.

  • Darwin Global Management's largest Q4 2025 buy was Belite Bio: 3,027,704 shares worth $487M.
  • Darwin Global Management added most to Insmed in Q4 2025, an estimated $86.8M increase.
  • Darwin Global Management fully exited United Therapeutics in Q4 2025, selling an estimated $318M.
  • Darwin Global Management's ten largest holdings make up 100% of its $4.94B portfolio in Q4 2025.
  • Darwin Global Management opened 3 new positions and closed 2 in Q4 2025.
  • Darwin Global Management's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Darwin Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.